Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
- PMID: 17935854
- DOI: 10.1016/j.biochi.2007.08.009
Alternative lengthening of telomeres (ALT) and chromatin: is there a connection?
Abstract
The acquisition of cellular immortality is a critical step in the tumorigenic process that requires stabilization of the telomeres, nucleoprotein structures at the termini of chromosomes. While the majority of human tumors stabilize their telomeres through activation of telomerase (hTERT), a significant portion (10-15%) utilize a poorly understood alternative mechanism of telomere maintenance referred to as ALT (Alternative Lengthening of Telomeres). Strikingly, the ALT mechanism is more prevalent in tumors arising from tissues of mesenchymal origin than in those of epithelial origin. This observation suggests that cell type specific mechanisms favor the activation of the ALT mechanism versus telomerase in human tumorigenesis. In addition, the presence of an alternative mechanism of telomere maintenance raises the possibility that telomerase-positive tumors undergoing anti-telomerase therapies might escape by activating the ALT pathway. For these reasons, delineating the ALT mechanism is critical for our understanding of the tumorigenic process and the development of ALT-specific anti-neoplastic therapies. Recent studies have demonstrated that epigenetic modifications at telomeres have a profound effect on telomere length, and may also be linked to the ALT mechanism. In this review we focus on these recent advances and their implications in telomere maintenance.
Similar articles
-
Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of the hTR and hTERT gene promoters.Cancer Res. 2005 Sep 1;65(17):7585-90. doi: 10.1158/0008-5472.CAN-05-1715. Cancer Res. 2005. PMID: 16140922
-
Telomere lengthening in telomerase-negative cells: the ends are coming together.Virchows Arch. 2002 Jun;440(6):573-82. doi: 10.1007/s00428-002-0634-9. Epub 2002 Apr 9. Virchows Arch. 2002. PMID: 12070595 Review.
-
Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT.Cancer Res. 2006 Apr 1;66(7):3584-92. doi: 10.1158/0008-5472.CAN-05-2839. Cancer Res. 2006. PMID: 16585183
-
Telomere maintenance and tumorigenesis: an "ALT"ernative road.Curr Mol Med. 2005 Mar;5(2):253-7. doi: 10.2174/1566524053586653. Curr Mol Med. 2005. PMID: 15974880 Review.
-
Telomere uncapping and alternative lengthening of telomeres.Mech Ageing Dev. 2008 Jan-Feb;129(1-2):99-108. doi: 10.1016/j.mad.2007.11.006. Epub 2007 Dec 8. Mech Ageing Dev. 2008. PMID: 18215414 Review.
Cited by
-
Cohesin SMC1beta protects telomeres in meiocytes.J Cell Biol. 2009 Oct 19;187(2):185-99. doi: 10.1083/jcb.200808016. J Cell Biol. 2009. PMID: 19841137 Free PMC article.
-
Zscan4 Contributes to Telomere Maintenance in Telomerase-Deficient Late Generation Mouse ESCs and Human ALT Cancer Cells.Cells. 2022 Jan 28;11(3):456. doi: 10.3390/cells11030456. Cells. 2022. PMID: 35159266 Free PMC article.
-
Inhibition of human telomerase reverse transcriptase in vivo and in vitro for retroviral vector-based antisense oligonucleotide therapy in ovarian cancer.Cancer Gene Ther. 2016 Jan;23(1):36-42. doi: 10.1038/cgt.2015.64. Epub 2016 Jan 8. Cancer Gene Ther. 2016. PMID: 26742579
-
BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells.Genes (Basel). 2019 Sep 10;10(9):697. doi: 10.3390/genes10090697. Genes (Basel). 2019. PMID: 31510074 Free PMC article.
-
Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?J Exp Clin Cancer Res. 2017 Dec 22;36(1):189. doi: 10.1186/s13046-017-0657-3. J Exp Clin Cancer Res. 2017. PMID: 29273061 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources